Germany· DE-A57-01e31f71be390fb0
Tapentadol Ratiopharm
A tapentadol product containing tapentadol tartrate, registered in Germany by Ratiopharm Gmbh. The same ATC class is registered in 17 of our 19 countries.
Checked against EMA Article 57 (European Union) on
Informational only — not a medical device.
Where it is registered
Tapentadol is registered in 17 of 19 countries.
Countries holding a registration under ATC N02AX06 (tapentadol), each read from that country’s own register.
- This record: Germany, from EMA Article 57 (European Union)
- 10 of them publish a price we can compare per daily dose
Tapentadol · ATC N02AX06
17 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of tapentadol costs, country by country.
Normalised to the WHO defined daily dose (0.4 g), the median price runs from $2.14 in Italy to $6.62 in Switzerland — a ×3.1 gap.
- 3 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Tapentadol · price per daily dose (0.4 g)
USD · FX 28 Sept 2026
- CH Switzerland$6.62
- ES Spain$3.34
- IT Italy$2.14
The record
At a glance
EMA Article 57 (European Union)- Active substance
- Tapentadol Tartrate
- Manufacturer
- Ratiopharm Gmbh
- Country
- Germany (DE)
- ATC code
- N02AX06
- ATC class
- Tapentadol
- Defined daily dose
- 0.4 g, O
- Reimbursed
- Not published by this register
- Source register
- EMA Article 57 (European Union)
- Last checked
- September 30, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
184 interactions on record for tapentadol.
Graded by severity as the source publishes them — 30 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Tapentadol · interactions on record
184 records
- 30 severe
- 130 moderate
Most severe, free to view
- OndansetronA04AA01severe
- GranisetronA04AA02severe
- DolasetronA04AA04severe
- PalonosetronA04AA05severe
24 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under N02AX06
Tapentadol, as other registers publish it.
- PolandAdobenKrka, d.d., Novo mesto
- PolandAdobenKrka, d.d., Novo mesto
- PolandAdobenKrka, d.d., Novo mesto
- PolandAdobenKrka, d.d., Novo mesto
- PolandAdobenKrka, d.d., Novo mesto
- CzechiaAPENETAKrka, d.d., Novo mesto, Novo mesto
- CzechiaAPENETAKrka, d.d., Novo mesto, Novo mesto
- CzechiaAPENETAKrka, d.d., Novo mesto, Novo mesto
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of EMA Article 57 (European Union). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f33ec3b6-7f38-4d13-b400-e69350a30189 GET /v1/drugs/f33ec3b6-7f38-4d13-b400-e69350a30189?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"pzn": null,
"route": "Oral Use",
"source": "ema_art57_de",
"ma_number": null,
"substance": "Tapentadol Tartrate",
"atc_from_source": null,
"authorisation_country": "Germany"
}See everything about tapentadol.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.